Key facts
- This page summarizes Brian G. Atwood's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2025, 19:12.
Brian G. Atwood - 31 Mar 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Reporting relationship
- Director
- Issuer ticker
- CERO
- Reported as of
- 31 Mar 2025
- Net transaction value
- +$58.89
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2025, 19:12:50 UTC
- Prior SEC filing
- 06 Mar 2025
- Next SEC filing
- 02 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian G. Atwood
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian G. Atwood filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 04 Apr 2025.
Change
- Previous filing in this sequence was filed on 06 Mar 2025.
- Current net transaction value: +$58.89.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CERO
transaction
Common Stock
Options Exercise
- Transaction value
- $29.45
- Shares
- +294,460
- Change %
- +150%
- Price
- $0.000100
- Shares after
- 490,534
- Date
- 31 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F1
CERO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,250
- Date
- 31 Mar 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERO
transaction
Derivative
Pre-Funded Warrant
Options Exercise
- Transaction value
- $29.45
- Shares
- +294,460
- Change %
- Price
- $0.000100
- Shares after
- 11,660
- Date
- 31 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 294,460
- Exercise price
- $0.000100
- Footnotes
- F2
CERO
holding
Derivative
Pre-Funded Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 204,080
- Date
- 31 Mar 2025
- Ownership
- By GVN, LLC
- Underlying class
- Common Stock
- Underlying amount
- 204,080
- Exercise price
- $0.000100
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On March 28, 2025, Mr. Atwood exercised Pre-Funded Warrants (the "Pre-Funded Warrants") and directed the issuance of the shares of common stock of CERo Therapeutics Holdings, Inc. (the "Issuer") to the Atwood-Edminster Trust dtd 4-2-2000 (the "Trust"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC..
Footnote F2
The Pre-Funded Warrants are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of the Issuer.
Footnote F3
GVN, LLC (the "LLC") is a limited liability company of which the sole member is the Trust..